Nosis Bio Head of Research to Speak at 2024 Cystic Fibrosis Research Conference

We’re excited to announce that Dr. Chad Miller, Head of Research at Nosis Bio, will be presenting  research at the 2024 Cystic Fibrosis Research Conference. This conference brings together top scientists, clinicians, and biotech leaders dedicated to advancing treatments for cystic fibrosis (CF) and improving the quality of life for patients affected by this challenging disease.

Dr. Miller’s presentation will focus on Nosis Bio’s latest work in targeted RNA-based therapies, specifically designed to address the unique cellular and genetic needs of cystic fibrosis patients. By developing RNA medicines that can selectively target and deliver therapeutic molecules directly to the cells most affected in CF, Nosis Bio aims to improve therapeutic outcomes and minimize off-target effects, offering a promising new approach to cystic fibrosis treatment.

Key highlights from Dr. Miller’s presentation include:

•Targeted Delivery of RNA Therapeutics to Lung Cells: An overview of Nosis Bio’s progress in engineering delivery vehicles that direct RNA molecules specifically to lung cells—one of the critical tissues impacted by CF. This precision-targeting approach aims to maximize the efficacy of treatment and reduce unwanted side effects.

•Leveraging Deep Learning for Precision Medicine: Dr. Miller will discuss how Nosis Bio’s deep learning platform enables the design of cell-specific delivery systems, ensuring that RNA-based treatments reach the intended cells with high accuracy.

•Potential Impact for Cystic Fibrosis Patients: With cystic fibrosis affecting respiratory function, targeting treatment directly to specific lung cells could represent a significant advancement in managing the disease’s symptoms and underlying causes, ultimately improving patient outcomes and quality of life.

Stay tuned as we continue our work to make precision-targeted RNA therapies a reality for cystic fibrosis and beyond.

‍